Benitec Biopharma Inc. (BNTC) - 10-K Summary
Business Context and Reporting Period
Company: Benitec Biopharma Inc.
Filing Type: Annual Report on Form 10-K
Reporting Period: Fiscal year ended June 30, 2026
Business Overview: Benitec is a clinical-stage biotechnology company developing novel genetic medicines using its proprietary "silence and replace" DNA-directed RNA interference (ddRNAi) platform. The company's lead product candidate, BB-301, is an AAV-based gene therapy designed to treat Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 has received Orphan Drug and Fast Track Designations in the U.S. and Orphan Drug Designation in the EU. The company has no approved products and has not generated any revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | Year Ended June 30, 2026 | Year Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(45,546) | $(37,917) |
| Operating Expenses | $51,192 | $41,765 |
| Research & Development | $23,388 | $18,332 |
| General & Administrative | $27,804 | $23,433 |
| Cash and Cash Equivalents (End of Period) | $179,972 | $97,744 |
| Accumulated Deficit | $(273,722) | $(228,176) |
| Net Cash Used in Operating Activities | $(16,518) | $(23,588) |
| Net Cash Provided by Financing Activities | $98,977 | $70,485 |
Liquidity: As of June 30, 2026, the company held approximately $180.0 million in cash and cash equivalents. Management estimates this is sufficient to fund operations for at least the next twelve months. The company has no borrowings or credit facilities.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $7.6 million (20%) year-over-year, driven primarily by higher operating expenses.
- Expense Growth: Total operating expenses rose by $9.4 million.
- R&D Expenses: Increased by $5.1 million, primarily due to a $6.3 million increase in share-based compensation and a $2.2 million increase in payroll, partially offset by a $3.8 million reduction in contract manufacturing costs.
- G&A Expenses: Increased by $4.4 million, driven by a $2.7 million increase in share-based compensation and a $0.8 million increase in payroll.
- Financing Activity: The company raised significant capital in fiscal 2026. In November 2025, it completed an underwritten offering and a concurrent registered direct offering, generating gross proceeds of approximately $104.5 million. This contrasts with fiscal 2025, which included a $30.5 million raise in March 2025.
- Interest Income: Net interest income increased by $2.3 million to $5.6 million, reflecting higher cash balances.
- One-Time Gain Removal: Fiscal 2025 included a $0.8 million gain on the extinguishment of liabilities from a vendor settlement; no comparable gain occurred in 2026.
Guidance, Outlook, and Risks
Outlook: The company expects to continue incurring significant operating losses for the foreseeable future as it advances BB-301 through clinical development. It anticipates increased expenses related to clinical trials, regulatory compliance, and general corporate operations. The company will require additional financing to progress its product candidates through future inflection points.
Management Commentary:
- BB-301 Phase 1b/2a clinical trial is ongoing. Cohort 1 subjects have completed the 12-month follow-up, and three subjects have been treated in Cohort 2.
- A Type C meeting with the FDA was held in Q3 2026 to discuss the pivotal study design.
- The company relies entirely on third-party manufacturers for its product candidates.
Risks and Contingencies:
- Going Concern: While cash is sufficient for 12 months, the company has a history of losses and no revenue. Future capital needs are uncertain.
- Internal Controls: The company previously identified a material weakness in internal controls related to share-based compensation calculations (resulting in a restatement of prior interim periods). Management believes this was remediated as of December 31, 2025, but notes that modified controls may not operate properly in the future.
- Regulatory & Clinical Risk: Success depends on the safety and efficacy of BB-301, which utilizes novel technology (ddRNAi) that has not yet been approved for commercial sale. Clinical trial delays or failures could materially harm the business.
- Intellectual Property: The company relies on a portfolio of patents and trade secrets; failure to protect these could allow competitors to develop similar products.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $180 million cash balance against the projected burn rate for the next 12 months and beyond, given the lack of revenue.
- Clinical Progress: Monitor the timeline and results of the BB-301 Phase 1b/2a trial, specifically the safety data from Cohort 2 and the FDA's feedback on the pivotal study design.
- Capital Requirements: Assess the likelihood and terms of future equity or debt financing required to fund the pivotal trial and potential commercialization.
- Internal Control Remediation: Confirm that the remediation of the share-based compensation material weakness remains effective and that no new material weaknesses have been identified.
- Share-Based Compensation: Review the significant portion of expenses attributed to share-based compensation ($26.4 million in 2026) and its impact on future dilution and cash flow.